StemWave Introduces Modus-F, A New FDA Listed Device With Cellular Response Therapy (CRT) Now Available For Orthopedic Use

March 28, 2022 – StemWave recently announced that their newest device Modus-F is now available for sale. StemWave recently received a Class l listing from the FDA and announced an exclusive North American partnership with Inceler Medikal, a leading global manufacturer.

StemWave’s newest product, Modus-F, uses uniquely designed Cellular Response Therapy (CRT) which utilizes an electrohydraulic system that generates focused acoustic waves that apply mechanical force and energy to living tissue.

StemWave will offer Modus-F to orthopedic healthcare providers like physical therapists, chiropractors, medical spas, and more.

Read more: https://www.digitaljournal.com/pr/stemwave-introduces-modus-f-a-new-fda-listed-device-with-area-directed-technology-adt-now-available-for-orthopedic-use#ixzz8HwIFJQMc